絞り込み

16548

広告

Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial.

著者 Corbalán R , Nicolau JC , López-Sendon J , Garcia-Castillo A , Botero R , Sotomora G , Horna M , Ruff CT , Hamershock RA , Grip LT , Antman EM , Braunwald E , Giugliano RP
J Am Coll Cardiol.2018 Sep 25 ; 72(13):1466-1475.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (39view , 0users)

Full Text Sources

Miscellaneous

There is limited information about the use of antithrombotic therapies and outcomes of Latin American (LatAm) subjects with atrial fibrillation. The global ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial compared the efficacy and safety of edoxaban versus warfarin over a median follow-up of 2.8 years.
PMID: 30236308 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード